SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines.
作者信息
Füessl Louise, Schönermarck Ulf
机构信息
Department of Medicine IV, University Hospital, LMU Munich.
出版信息
Lancet Reg Health Eur. 2022 Sep 13;21:100491. doi: 10.1016/j.lanepe.2022.100491. eCollection 2022 Oct.
Abstract
摘要
相似文献
1
SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines.血液透析患者中的新型冠状病毒2型疫苗接种：一项比较信使核糖核酸疫苗和病毒载体疫苗的前瞻性研究内情
Lancet Reg Health Eur. 2022 Sep 13;21:100491. doi: 10.1016/j.lanepe.2022.100491. eCollection 2022 Oct.
2
Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study.血液透析患者接种 mRNA 基于 SARS-CoV-2 疫苗后第一剂和第二剂后 IgG 抗体水平的时间依赖性演变：一项多中心研究。
Nephrol Dial Transplant. 2022 Jan 25;37(2):375-381. doi: 10.1093/ndt/gfab293.
3
Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls.血液透析患者在接种 COVID-19 mRNA 疫苗后的抗体反应明显低于健康对照者。
Nephrol Dial Transplant. 2021 Aug 27;36(9):1709-1716. doi: 10.1093/ndt/gfab179.
4
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.针对多发性硬化症患者的 SARS-CoV-2 灭活疫苗和 mRNA 疫苗的安全性和体液免疫应答率。
Mult Scler Relat Disord. 2022 Mar;59:103690. doi: 10.1016/j.msard.2022.103690. Epub 2022 Feb 13.
5
Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: A prospective, longitudinal cohort study in the Netherlands.比较四种新冠疫苗接种后母乳中的抗体反应：荷兰一项前瞻性纵向队列研究。
EClinicalMedicine. 2022 May;47:101393. doi: 10.1016/j.eclinm.2022.101393. Epub 2022 Apr 18.
6
Antibody response to mRNA SARS-CoV-2 vaccines in haemodialysis patients.血液透析患者对SARS-CoV-2 mRNA疫苗的抗体反应。
Clin Kidney J. 2021 Jul 6;14(10):2234-2238. doi: 10.1093/ckj/sfab127. eCollection 2021 Oct.
7
Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients.接种疫苗的肾移植和血液透析患者中严重突破性 SARS-CoV-2 感染的发生率。
J Nephrol. 2022 Apr;35(3):769-778. doi: 10.1007/s40620-022-01257-5. Epub 2022 Feb 21.
8
Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?对常规抗病毒疫苗的抗体反应不理想的个体能否从 SARS-CoV-2 mRNA 疫苗接种中获得足够的抗体？
Viruses. 2022 May 3;14(5):956. doi: 10.3390/v14050956.
9
Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.肾移植受者同源与异源第三剂疫苗接种后 4 周时的 SARS-CoV-2 抗体反应比较：一项随机临床试验。
JAMA Intern Med. 2022 Feb 1;182(2):165-171. doi: 10.1001/jamainternmed.2021.7372.
10
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. 异源加强免疫与同源加强免疫在原发性 mRNA 疫苗接种后未发生 SARS-CoV-2 抗体血清转化的免疫抑制患者中的效果比较：一项随机对照试验。
Ann Rheum Dis. 2022 May;81(5):687-694. doi: 10.1136/annrheumdis-2021-221558. Epub 2022 Jan 13.
本文引用的文献
1
Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study.BNT162b2和ChAdOx1新冠病毒疫苗在接受血液透析的终末期肾病患者中的免疫原性和临床有效性比较：一项前瞻性观察队列研究。
Lancet Reg Health Eur. 2022 Oct;21:100478. doi: 10.1016/j.lanepe.2022.100478. Epub 2022 Sep 10.
2
Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）加强疫苗接种后，有或无既往感染的血液透析患者的体液免疫反应
Clin Kidney J. 2022 May 24;15(8):1633-1635. doi: 10.1093/ckj/sfac148. eCollection 2022 Aug.
3
Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients.透析患者接种 BNT162b2 疫苗第三剂和第四剂后体液免疫反应和 SARS-CoV-2 感染风险。
Am J Nephrol. 2022;53(7):586-590. doi: 10.1159/000525309. Epub 2022 Jul 18.
4
Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses.在接受4剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗免疫的血液透析患者中，与SARS-CoV-2野生型相比，针对奥密克戎和德尔塔变异株的细胞免疫和体液免疫较低。
Kidney Int. 2022 Jul;102(1):207-208. doi: 10.1016/j.kint.2022.05.004. Epub 2022 May 14.
5
Humoral response after a fourth "booster" dose of a Coronavirus disease 2019 vaccine following a 3-dose regimen of mRNA-based vaccination in dialysis patients.在透析患者中，基于mRNA的疫苗接种3剂方案后，接种第4剂2019冠状病毒病疫苗“加强针”后的体液免疫反应。
Kidney Int. 2022 Jun;101(6):1289-1290. doi: 10.1016/j.kint.2022.04.006. Epub 2022 Apr 12.
6
Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses.与接种4剂相比，接种3剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的血液透析患者对野生型和奥密克戎变异株的体液免疫较低，细胞免疫持续存在。
Kidney Int. 2022 Jun;101(6):1287-1289. doi: 10.1016/j.kint.2022.03.005. Epub 2022 Mar 14.
7
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.COVID-19 与透析：临床影响、免疫反应、预防和治疗。
Kidney Int. 2022 May;101(5):883-894. doi: 10.1016/j.kint.2022.01.022. Epub 2022 Feb 14.
8
Heterologous versus homologous triple anti-COVID-19 vaccine regimens in patients on maintenance haemodialysis.维持性血液透析患者中异源与同源三联抗COVID-19疫苗接种方案
Nephrol Dial Transplant. 2022 Jun 23;37(7):1384-1386. doi: 10.1093/ndt/gfac033.
9
Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.mRNA 疫苗 BNT162b2 与腺病毒载体疫苗 Ad26.COV2.S 预防透析患者 COVID-19 的效果比较。
J Am Soc Nephrol. 2022 Apr;33(4):688-697. doi: 10.1681/ASN.2021101395. Epub 2022 Feb 8.
10
COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection.接种疫苗患者的血液透析单元 COVID-19 爆发：抗体滴度作为感染保护的标志物。
Nephrol Dial Transplant. 2022 Jun 23;37(7):1357-1365. doi: 10.1093/ndt/gfac016.
Zotero 插件